In the context of HIV-1, HSCT presents a unique opportunity to replace the host immune system with donor-derived cells that are intrinsically resistant to HIV-1 infection, primarily due to genetic mutations such as the CCR5 delta-32 deletion [23]. This evidence concerns the gene CCR5 and HIV-1 infection.